Novo Nordisk (NYSE:NVO) is a prominent player in the global healthcare sector, specializing in diabetes care and hormone replacement therapies. The company is renowned for its innovative GLP-1 drugs, Ozempic and Wegovy, which target type II diabetes and obesity. Despite its strong market presence, Novo Nordisk faces stiff competition from other pharmaceutical giants like Eli Lilly and Sanofi.
On February 12, 2026, Jefferies upgraded Novo Nordisk's stock from "Underperform" to "Hold," with the stock priced at $48.74. This upgrade comes amid a challenging outlook for 2026, as the company anticipates a slowdown in sales for its key drugs, Ozempic and Wegovy. Despite a successful launch of oral Wegovy, Novo Nordisk expects adjusted sales and operating profits to drop by 5-13% at constant exchange rates, excluding a $4.2 billion rebate reversal.
The anticipated decline in sales is due to several factors, including pricing pressure in the U.S., increased competition, foreign exchange headwinds, and higher research and development spending. Despite these challenges, Novo Nordisk reported strong results for the fourth quarter and the full year of 2025. The company saw significant contributions from its semaglutide-based GLP-1 drugs, which generated 206.2 billion Danish kroner in 2025, with 53.7 billion coming from the fourth quarter alone.
However, the sales momentum for these drugs has slowed over the past year, largely due to increasing competition. The current price of NVO is $48.74, reflecting a decrease of 0.38, or approximately -0.77%. Today, the stock has traded as low as $48.08 and as high as $48.96. Over the past year, NVO has reached a high of $93.80 and a low of $43.08, with a market capitalization of approximately $216.73 billion. Today's trading volume for NVO is 12,087,135 shares.
